STOCK TITAN

Lexeo Therapeutics director gets 70,000-share option grant

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. (LXEO) director Tobin Schilke received an option grant covering 70,000 shares of common stock on November 14, 2026, at an exercise price of $2.87 per share. One-third of the underlying shares vests and becomes exercisable on each yearly anniversary of the grant date; all are scheduled to be vested and exercisable on November 14, 2029, subject to continuous service on each vesting date. The options expire on November 13, 2036.

Insider Schilke Tobin
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) F1 70,000 $0.00 $0.00
Holdings After Transaction: Stock Option (right to buy) — 70,000 options (Direct)
Footnotes (1)
  1. F1. 1/3rd of the shares underlying the option shall vest, and become exercisable, on each yearly anniversary of the Grant Date, such that all shares are vested and exercisable on November 14, 2029, subject to the Reporting Person's continuous service on each such vesting date.
Option grant 70,000 shares Options granted to Tobin Schilke on November 14, 2026
Exercise price $2.87 per share Price to exercise the options
Annual vesting installment One-third of the underlying shares Vests and becomes exercisable on each yearly anniversary of the grant date, subject to continuous service
Full vesting and exercisability date November 14, 2029 All underlying shares are scheduled to be vested and exercisable, subject to continuous service on each vesting date
Option expiration date November 13, 2036 Expiration date of the options
Stock Option (right to buy) technical
"grant of Stock Option (right to buy)"
vest technical
"1/3rd of the shares underlying the option shall vest"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
exercisable technical
"all shares are vested and exercisable"
continuous service technical
"subject to the Reporting Person's continuous service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did LXEO director Tobin Schilke receive, and what is the exercise price?

Tobin Schilke received options covering 70,000 shares of common stock at an exercise price of $2.87 per share on November 14, 2026.

When do Tobin Schilke’s LXEO options vest?

One-third of the underlying shares vests and becomes exercisable on each yearly anniversary of the grant date, with all shares vested and exercisable on November 14, 2029, subject to continuous service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Schilke Tobin

(Last)(First)(Middle)
C/O LEXEO THERAPEUTICS, INC.
345 PARK AVENUE SOUTH, FLOOR 6

(Street)
NEW YORK NEW YORK 10010

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/14/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$2.8711/14/2026A70,000 (1)11/13/2036Common Stock70,000$070,000D
Explanation of Responses:
1. 1/3rd of the shares underlying the option shall vest, and become exercisable, on each yearly anniversary of the Grant Date, such that all shares are vested and exercisable on November 14, 2029, subject to the Reporting Person's continuous service on each such vesting date.
/s/ Youjin Choi, Attorney-in-Fact11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading